Skip to main content

Advertisement

SpringerLink
Log in

What Is the Hypertension “Phenotype”?

  • Hypertension (R Townsend, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Today, the characterization of the hypertension phenotype relies essentially on the repeated measurement of blood pressure in the physician’s office. Blood pressure values acquired in these conditions have been shown to correlate with the cardiovascular outcome and the risk of developing hypertension-induced target organ damages. However, the limitations of office blood pressure are now well recognized and there is increasing evidence that other components of blood pressure may help to improve the determination of the hypertensive phenotype. This starts with the monitoring of blood pressure outside the office using either 24-h ambulatory or home blood pressure monitoring. With these new diagnostic tools, new phenotypes of hypertension have been identified such as white coat hypertension and masked hypertension which carry different risks of hypertensive complications. More recently, the ability to measure central blood pressure has further questioned the pertinence of continuing to measure only office blood pressure in hypertension. There is no doubt today that these new possibilities to complete the hypertension phenotype should be sometimes introduced in clinical practice when the evidence of added value is strong. However, there is a huge need for physicians’ education before these new parameters can be integrated in the daily management of hypertensive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mancia G, Zanchetti A. One hundred years of auscultatory blood pressure: commemorating N. S. Korotkoff. J Hypertens. 2005;23(1):1–2.

    Article  CAS  PubMed  Google Scholar 

  2. Janeway TC. A clinical study of hypertensive cardiovascular disease. Arch Int Med. 1913;12:755.

    Article  Google Scholar 

  3. Society of Actuaries. Blood pressure: report of the Joint Committee on Mortality of the Association of Life Insurance Medical Directors and the Actuarial Society of America. New York: Society of Actuaries; 1925.

    Google Scholar 

  4. Shantsila A, Shantsila E, Lip GY. Malignant hypertension: a rare problem or is it underdiagnosed? Curr Vasc Pharmacol. 2010;8(6):775–9.

    Article  CAS  PubMed  Google Scholar 

  5. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension. I: results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 1967; 202 :1028

  6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.

    Article  PubMed  Google Scholar 

  7. O’Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697–701.

    Article  PubMed  Google Scholar 

  8. Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension. 2010;55:195–200.

    Article  CAS  PubMed  Google Scholar 

  9. Manzoli L, Simonetti V, D’Errico M, De Vito C, Flacco ME, Forni C, et al. (In)accuracy of blood pressure measurement in 14 Italian hospitals. J Hypertens. 2012;30:1955–60.

    Article  CAS  PubMed  Google Scholar 

  10. Burnier M. Blood pressure in hospitalized patients: should we still measure it? J Hypertens. 2012;30(10):1913–4.

    Article  CAS  PubMed  Google Scholar 

  11. Burnier M, Gasser UE. End-digit preference in general practice: a comparison of the conventional auscultatory and electronic oscillometric methods. Blood Press. 2008;17(2):104–9.

    Article  PubMed  Google Scholar 

  12. Gerc V, Favrat B, Brunner HR, Burnier M. Is nurse-measured blood pressure a valid substitute for ambulatory blood pressure monitoring? Blood Press Monit. 2000;5(4):203–9.

    Article  CAS  PubMed  Google Scholar 

  13. Mancia G, Zanchetti A. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation. 1997;95:1464–70.

    Article  CAS  PubMed  Google Scholar 

  14. Abe H, Yokouchi M, Saitoh F, et al. Hypertensive complications and home blood pressure: comparison with blood pressure measured in the doctor’s office. J Clin Hypertens. 1987;3:661–9.

    CAS  PubMed  Google Scholar 

  15. Shimbo D, Pickering TG, Spruill TM, Abraham D, Schwartz JE, Gerin W. Relative utility of home, ambulatory, and office blood pressures in the prediction of end-organ damage. Am J Hypertens. 2007;20:476–82.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama. Japan J Hypertens. 1998;16:971–5.

    Article  CAS  Google Scholar 

  17. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846–53.

    Article  CAS  PubMed  Google Scholar 

  18. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA). Study Circulation. 2005;111:1777–83.

    Article  Google Scholar 

  19. Parati G, Omboni S, Bilo G. Why is out-of-office blood pressure measurement needed?: home blood pressure measurements will increasingly replace ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Hypertension. 2009;54:181–7. Excellent discussion on why we need out-of-office BP measurements and good comparison of the different techniques.

    Article  CAS  Google Scholar 

  20. Mancia G, Zanchetti A, Agabiti RE, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on ambulatory monitoring of blood pressure and lisinopril evaluation. Circulation. 1997;95:1464–70.

    Article  CAS  PubMed  Google Scholar 

  21. Rave K, Bender R, Heise T, Sawicki PT. Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy. J Hypertens. 1999;17:597–601.

    Article  CAS  PubMed  Google Scholar 

  22. Waeber B, Scherrer U, Petrillo A, et al. Are some hypertensive patients overtreated? A prospective study of ambulatory blood pressure recording. Lancet. 1987;2(8561):732–4.

    Article  CAS  PubMed  Google Scholar 

  23. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension. 2000;35:844–51.

    Article  CAS  PubMed  Google Scholar 

  24. Clement DL, De Buyzere ML, De Bacquer DA, Office versus Ambulatory Pressure Study Investigators, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.

    Article  PubMed  Google Scholar 

  25. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779–85.

    Article  CAS  PubMed  Google Scholar 

  26. Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359–66. Most recent updated guidelines on the use of ABPM.

    Article  CAS  PubMed  Google Scholar 

  27. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.

    Article  PubMed  Google Scholar 

  28. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Home blood pressure measurements will not replace 24-hour ambulatory blood pressure monitoring. Hypertension. 2009;54:188–95.

    Article  CAS  Google Scholar 

  29. Verdecchia P, Schillaci G, Borgioni C, et al. White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens. 1995;8:790–8.

    Article  CAS  PubMed  Google Scholar 

  30. Franklin SS, Thijs L, Hansen TW, O’Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. Hypertension. 2013;62(6):982–7.

    Article  CAS  PubMed  Google Scholar 

  31. Bidlingmeyer I, Burnier M, Bidlingmeyer M, Waeber B, Brunner HR. Isolated office hypertension: a prehypertensive state? J Hypertens. 1996;14(3):327–32.

    Article  CAS  PubMed  Google Scholar 

  32. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 2002;40(6):795–6.

    Article  CAS  PubMed  Google Scholar 

  33. Peacock J, Diaz KM, Viera AJ, Schwartz JE, Shimbo D. Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens. 2014;28(9):521–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension. 2009;53(1):20–7.

    Article  CAS  PubMed  Google Scholar 

  35. Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension. 2013;61(5):964–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Baguet JP, Levy P, Barone-Rochette G, et al. Masked hypertension in obstructive sleep apnea syndrome. J Hypertens. 2008;26(5):885–92.

    Article  CAS  PubMed  Google Scholar 

  37. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25(11):2193–8.

    Article  CAS  PubMed  Google Scholar 

  38. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291:1342–9.

    Article  CAS  PubMed  Google Scholar 

  39. Alwan H, Pruijm M, Ponte B, et al. Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study. PLoS One. 2014;9(3):e92522. doi:10.1371/journal.pone.0092522.eCollection 2014.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Burnier M, Coltamai L, Maillard M, Bochud M. Renal sodium handling and nighttime blood pressure. Semin Nephrol. 2007;27(5):565–71.

    Article  CAS  PubMed  Google Scholar 

  41. Tsai DH, Riediker M, Wuerzner G, et al. Short-term increase in particulate matter blunts nocturnal blood pressure dipping and daytime urinary sodium excretion. Hypertension. 2012;60(4):1061–9.

    Article  CAS  PubMed  Google Scholar 

  42. Fukuda M, Goto N, Kimura G. Hypothesis on renal mechanism of non-dipper pattern of circadian blood pressure rhythm. Med Hypotheses. 2006;67:802–6.

    Article  PubMed  Google Scholar 

  43. Ohkubo T, Imai Y, Tsuji I, et al. Relation between nocturnal decline in blood pressure and mortality: the Ohasama Study. Am J Hypertens. 1997;10:1201–7.

    Article  CAS  PubMed  Google Scholar 

  44. Hoshide Y, Kario K, Schwartz JE, Hoshide S, Pickering TG, Shimada K. Incomplete benefit of antihypertensive therapy on stroke reduction in older hypertensives with abnormal nocturnal blood pressure dipping (extreme-dippers and reverse-dippers). Am J Hypertens. 2002;15:844–50.

    Article  PubMed  Google Scholar 

  45. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55–61.

    Article  CAS  PubMed  Google Scholar 

  46. Uzu T, Ishikawa K, Fujii T, et al. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1997;96:1859–62.

    Article  CAS  PubMed  Google Scholar 

  47. Wuerzner G, Bochud M, Zweiacker C, Tremblay S, Pruijm M, Burnier M. Step count is associated with lower nighttime systolic blood pressure and increased dipping. Am J Hypertens. 2013;26(4):527–34.

    Article  PubMed  Google Scholar 

  48. Roush GC, Fapohunda J, Kostis JB. Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens (Greenwich). 2014;16(8):561–8.

    Article  CAS  Google Scholar 

  49. Safar ME, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and cardiovascular disease—is it possible to break the vicious circle? Atherosclerosis. 2011;218(2):263–71.

    Article  CAS  PubMed  Google Scholar 

  50. Narayan O, Casan J, Szarski M, Dart AM, Meredith IT, Cameron JD. Estimation of central aortic blood pressure: a systematic meta-analysis of available techniques. J Hypertens. 2014;32(9):1727–40. A good description of the various techniques actually available for the determination of central blood pressure.

    Article  CAS  PubMed  Google Scholar 

  51. Herbert A, Cruickshank JK, Laurent S, Boutouyrie P, on behalf of The Reference Values for Arterial Measurements Collaboration, on behalf of The Reference Values for Arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J. 2014;11.

  52. Cheng HM, Chuang SY, Sung SH, et al. Derivation and validation of diagnostic thresholds for central blood pressure measurements based on long-term cardiovascular risks. J Am Coll Cardiol. 2013;62(19):1780–7.

    Article  PubMed  Google Scholar 

  53. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197–203.

    Article  CAS  PubMed  Google Scholar 

  54. Wang KL, Cheng HM, Chuang SY, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27(3):461–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39:735–8.

    Article  CAS  PubMed  Google Scholar 

  56. Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010;31:1865–71.

    Article  PubMed  Google Scholar 

  57. Tomlinson LA, Wilkinson IB. Does it matter where we measure blood pressure? Br J Clin Pharmacol. 2012;74(2):241–5.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol. 2013;75(1):79–92. An excellent meta-analysis of the effect of drugs on central blood pressure.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, Mayet J, et al. Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. Hypertension. 2009;54(4):724–30.

    Article  CAS  PubMed  Google Scholar 

  60. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213–25.

    Article  CAS  PubMed  Google Scholar 

  61. Kelly R, Daley J, Avolio A, O’Rourke M. Arterial dilation and reduced wave reflection. Benefit of dilevalol in hypertension. Hypertension. 1989;14:14–21.

    Article  CAS  PubMed  Google Scholar 

  62. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351–6.

    Article  CAS  PubMed  Google Scholar 

  63. Sharman JE, Marwick TH, Gilroy D, Otahal P, Abhayaratna WP, Stowasser M, et al. Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. Hypertension. 2013;62(6):1138–45. First attempt to demonstrate the benefits of managing hypertensive patients based on centrally measured BP.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Michel Burnier and Grégoire Wuerzner have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Service of Nephrology and Hypertension, Department of Medicine, University Hospital, Rue du Bugnon 17, CHUV, 1011, Lausanne, Switzerland

    Michel Burnier & Grégoire Wuerzner

Authors
  1. Michel Burnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grégoire Wuerzner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Burnier.

Additional information

This article is part of the Topical Collection on Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burnier, M., Wuerzner, G. What Is the Hypertension “Phenotype”?. Curr Cardiovasc Risk Rep 9, 9 (2015). https://doi.org/10.1007/s12170-015-0438-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-015-0438-5

Keywords

Search

Navigation